Aducanumab

Aducanumab

The Biogen Aduhelm mess could happen again. A doctor who treats people with Alzheimer's doesn't blame Biogen for the Aduhelm mess. He blames the FDA.

Aducanumab, developed by Biogen, is a drug that has been making headlines in the field of Alzheimer's treatment. It has generated both excitement and controversy due to its potential to slow down the progression of the disease. However, the FDA's approval of Aducanumab has sparked a heated debate among healthcare professionals and experts.

While some believe that the drug offers hope for Alzheimer's patients and their families, others are concerned about its efficacy and the potential risks associated with its use. The controversy surrounding Aducanumab highlights the challenges faced by regulatory agencies in evaluating and approving new drugs for complex conditions like Alzheimer's.